Your browser doesn't support javascript.
Antibody multispecificity: A necessary evil?
Jaiswal, Deepika; Verma, Sheenam; Nair, Deepak T; Salunke, Dinakar M.
  • Jaiswal D; International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India.
  • Verma S; Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India.
  • Nair DT; Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India.
  • Salunke DM; International Centre for Genetic Engineering and Biotechnology, Aruna Asaf Ali Marg, New Delhi 110067, India. Electronic address: dinakar.salunke55@gmail.com.
Mol Immunol ; 152: 153-161, 2022 12.
Article in English | MEDLINE | ID: covidwho-2264341
ABSTRACT
Antibodies represent key effectors of the adaptive immune system. The specificity of antibodies is an established hallmark of the immune response. However, a certain proportion of antibodies exhibit limited promiscuity or multireactivity. Germline antibodies display plasticity which imparts multispecificity to enhance the antibody repertoire. Surprisingly, even affinity matured antibodies display such plasticity and multireactivity enabling their binding to more than one antigen. We propose that antibody multispecificity is a physiological requirement to expand the antibody repertoire at the germline level and to tolerate plasticity in antigens at the mature level. This property of the humoral immune response may attenuate the ability of infectious RNA viruses such as influenza, HIV and SARS-CoV-2 to acquire mutations that render resistance to neutralizing antibodies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Mol Immunol Year: 2022 Document Type: Article Affiliation country: J.molimm.2022.10.012

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: English Journal: Mol Immunol Year: 2022 Document Type: Article Affiliation country: J.molimm.2022.10.012